Rijnstate Hospital
Arnhem, Netherlands
NCT Number: NCT04972357
Gastric emptying measured with scintigraphy in patients after standard Roux-en-Y Gastric Bypass (S-RYGB), Banded-RYGB (B-RYGB) or Extended pouch-RYGB (E-RYGB).
Looking for future studies?
Notify MeFemale
Observational
Arnhem, Netherlands
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Female patients who underwent S-RYGB, B-RYGB or E-RYGB as a primary bariatric surgery.
Exclusion criteria
(1) had a disease known to affect appetite, gastric emptying or gastrointestinal motility (e.g., diabetes mellitus or hyper-/hypothyroidism); (2) were unable to stop medications that affect gastric emptying and/or motility three days prior to measurements (e.g., anti-cholinergic drugs, prokinetics, theophylline, calcium blocking agents, opioids); (3) started menopause; (4) were pregnant or lactating; (5) had a drug or alcohol addiction; (6) were unable to stop smoking for 24 hours.
Time frame: cross-sectional study. Measured once over a period of 45-60 minutes
Rijnstate Hospital
Other
Bariatric Procedures and Changes in Gut Hormone and Gastric Passage
Acronym: BIP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06407193
Bariatric Surgery, Gastric Emptying
Arnhem, Gelderland, Netherlands
View Trial DetailsNCT06391255
Bariatric Surgery, Gastric Emptying
Arnhem, Gelderland, Netherlands
View Trial DetailsNCT05977244
Dyslipidemias, Gastric Emptying
Kuala Lumpur, Malaysia
View Trial DetailsNCT07451015
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tanta, Gharbia Governorate, Egypt
View Trial Details